Cardiovascular disease burden in Turkey is projected to increase from 3.4 million affected adults in 2016 to 5.4 million by 2035, with economic costs doubling to US$19.4 billion.
The prevalence and economic burden of cardiovascular disease in Turkey are projected to increase significantly by 2035, highlighting the need for public health interventions.
OBJECTIVE: This study aims to estimate the current and future burden of cardiovascular diseases (CVD) in Turkey. METHODS: A burden-of-disease model was developed that included inputs on population growth, prevalence, and incidence of ischemic disease (IHD) and cerebrovascular disease (CeVD), prevalence of modifiable risk factors, mortality rates, and relationship between risk factors and IHD/CeVD. Direct costs to the public health-care system and indirect costs from lost production due to premature mortality, hospitalizations, disability, and absenteeism were considered. RESULTS: We estimated that in 2016, 3. 4 million Turkish adults were living with CVD, including 2. 5 million affected by IHD, and 0. 9 million by CeVD. This prevalence is projected to increase to 5. 4 million by 2035. The economic burden of CVD was estimated at US10. 2 billion in 2016, projected to increase twofold to US19. 4 billion by 2035. CONCLUSION: Our study confirms that the current burden of CVD is significant, and that it is projected to increase at a steep rate over the next two decades. This growing burden of disease will likely create significant pressure on the public health-care system in the form of direct health-care costs, as well as on society in the form of lost productivity.
Yücel Balbay (Mon,) conducted a other in Cardiovascular disease (CVD). Cardiovascular disease burden in Turkey is projected to increase from 3.4 million affected adults in 2016 to 5.4 million by 2035, with economic costs doubling to US$19.4 billion.